Deoxypyridinoline is one of the metabolites produced during bone resorption. Deoxypyridinoline excretion, unlike other markers, is not affected by diet, or the activity level of other tissues. In postmenopausic women, increased excretion of deoxypyridinoline has been associated with increased bone mass loss. The objective of this study was to determine the association of deoxypyridinoline excretion in postmenopausic Mexican women with anthropometric factors, bone mass density, calcium and phosphorous intakes, post menopause years and serum levels of estradiol. The concentration of deoxypyridinoline in 24 h urine was determined utilizing an ELISA technique. An average of 7,27 +/- 5,31 nM Dpd/mM creatinine was found. A negative correlation between deoxypyridinoline and serum estradiol levels (r = -0.37, p = 0.01) was found. Post menopausic years correlated positively (r = .35, p = 0.02) with Dpd. No significant correlation between deoxypyridinoline and anthropometric data, bone mass density, calcium and phosphorous intakes was found. In conclusion, 30% of the subjects of this study had elevated levels of deoxypyridinoline excretion and taking into consideration the negative correlation observed with serum estradiol, this segment of the population could be at risk for accelerated bone loss. Hormone replacement is important for post menopausic women to prevent increased bone loss.